2C:ARA8 | Subcutaneous, Lymph Node‐Directed, Liposome Antigen‐Specific Immunotherapy Enables Immune Regulation and Disease Suppression in Autoimmune Arthritis
International Journal of Rheumatic Diseases · 2026-05 · 29 (S2)
DOI: 10.1111/1756-185x.70608_7 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 11.05.2026.
Abstract (Originalsprache)
Aims: Achieving sustained drug-free remission remains a major unmet goal in RA. Current DMARDs suppress inflammation but fail to restore immune tolerance, leading to disease relapse after treatment withdrawal. Antigen-specific immuno-therapy (ASI) aims to re-establish immune tolerance by delivering disease-relevant CD4 + T-cell epitopes to antigen-presenting cells (APCs) in an immunomodulatory context. Liposomal ASI platforms co-encapsulating self-antigen and NF-κ B inhibitors show promise in regulating autoimmune responses; however, achieving stable in vivo delivery of multiple active components to lymph nodes without direct lymph node injection remains a key translational challenge
Zitieren
APA
(2026). 2C:ARA8 | Subcutaneous, Lymph Node‐Directed, Liposome Antigen‐Specific Immunotherapy Enables Immune Regulation and Disease Suppression in Autoimmune Arthritis. International Journal of Rheumatic Diseases, 29(S2). https://doi.org/10.1111/1756-185x.70608_7
Vancouver
2C:ARA8 | Subcutaneous, Lymph Node‐Directed, Liposome Antigen‐Specific Immunotherapy Enables Immune Regulation and Disease Suppression in Autoimmune Arthritis. International Journal of Rheumatic Diseases. 2026;29(S2). doi:10.1111/1756-185x.70608_7
BibTeX
@article{euvimed2026,
title = {2C:ARA8 | Subcutaneous, Lymph Node‐Directed, Liposome Antigen‐Specific Immunotherapy Enables Immune Regulation and Disease Suppression in Autoimmune Arthritis},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {S2},
doi = {10.1111/1756-185x.70608_7}
}
EUVIMED